Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Neurol Sci ; 42(2): 727-729, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-33006724

RESUMEN

Coffin-Siris syndrome is a rare genetic disorder defined by the presence of particular facial traits, congenital malformations, intellectual disability, and speech impairment. Epilepsy in Coffin-Siris syndrome has only occasionally been reported, and its features are poorly defined. We provide a detailed description of the clinical and instrumental findings of three patients with Coffin-Siris syndrome and epilepsy. The clinical diagnosis in our patients was confirmed by molecular analysis, which identified the presence of de novo mutations of ARID1B and SMARCB1 genes, in two patients and one patient, respectively. All the patients presented with epilepsy, with a mean age of seizure onset of 5.5 years. Seizures were brief and had a focal onset with secondary generalization. Electroencephalographic recording documented a unilateral, and less commonly bilateral, paroxysmal activity in the temporal, parietal, and occipital regions. Clinical response to anticonvulsive therapy was satisfactory, with a low rate of seizure recurrence. Our case series contributes to delineate the phenotype of Coffin-Siris syndrome. We wish this report could pave the way for further studies that will better define the prevalence and clinical manifestations of epilepsy in this rare syndrome.


Asunto(s)
Epilepsia , Discapacidad Intelectual , Anomalías Múltiples , Preescolar , Proteínas Cromosómicas no Histona , Proteínas de Unión al ADN , Epilepsia/genética , Cara/anomalías , Deformidades Congénitas de la Mano , Humanos , Discapacidad Intelectual/diagnóstico , Discapacidad Intelectual/genética , Micrognatismo , Cuello/anomalías
2.
Neurol Sci ; 41(2): 457-458, 2020 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-31654361

RESUMEN

We report the case of a 3.6-year-old male child who developed progressive hyposthenia of the left lower limb. Symptoms were preceded by rhinitis, malaise, and fever. Brain and spinal magnetic resonance imaging revealed diffuse signal abnormalities compatible with a subacute myeloencephalitis. A diagnostic lumbar puncture was performed and followed by an empirical therapy including Acyclovir, Ceftriaxone, and Clarithromycin. The cerebrospinal fluid analysis revealed clear fluid, glucose, proteins, albumin within the reference range, and 144 leukocytes/mm3. Oligoclonal bands were absent and a search for viruses was negative. Wide microbiological surveillance was performed on surface swabs, blood, urine, and stool. Both nasal and pharyngeal swabs were positive for PicoRNAvirus: sequencing identified Rhinovirus A44. This virus has been detected in association with acute flaccid paralysis in only a few patients worldwide, whereas in the great majority of patients with acute flaccid paralysis other Enterovirus species were identified. The most appropriate therapeutic approach towards acute flaccid paralysis is still a matter of debate in the scientific community, with no current definitivere commendations available. With a combined immunosuppressive and anti-inflammatory therapy including intravenous immunoglobulins, intravenous Methylprednisolone, oral Prednisone, and oral Ibuprofen, we experienced a positive outcome both from the clinical point of view and from three-month follow-up imaging studies. Given the rarity and the complexity of this condition, additional studies are needed to better define the potential role of Rhinovirus A44 in the pathogenesis of the disease and the efficacy of any therapeutic measure in the management of acute flaccid paralysis.


Asunto(s)
Enfermedades Virales del Sistema Nervioso Central/diagnóstico , Mielitis/diagnóstico , Enfermedades Neuromusculares/diagnóstico , Infecciones por Picornaviridae/diagnóstico , Rhinovirus/patogenicidad , Enfermedades Virales del Sistema Nervioso Central/etiología , Enfermedades Virales del Sistema Nervioso Central/virología , Preescolar , Humanos , Masculino , Mielitis/etiología , Mielitis/virología , Enfermedades Neuromusculares/etiología , Enfermedades Neuromusculares/virología , Infecciones por Picornaviridae/complicaciones , Infecciones por Picornaviridae/virología , Rhinovirus/aislamiento & purificación
3.
J Clin Med ; 13(9)2024 Apr 29.
Artículo en Inglés | MEDLINE | ID: mdl-38731144

RESUMEN

Recurrent headaches, encompassing migraine and tension-type headaches, represent prevalent conditions affecting individuals across different age groups, exerting a substantial influence on daily functioning and quality of life. Headaches serve as common manifestations of underlying health issues. Among these, celiac disease, an autoimmune disorder activated by gluten consumption, has emerged as a noteworthy concern. Recent research indicates a correlation between celiac disease and heightened susceptibility to headaches, particularly migraines. Celiac disease (CD) is an immune-mediated systemic, widespread disorder presenting a heterogeneous constellation of symptoms with a relatively easy diagnosis and therapy. Among signs and symptoms exhibited in celiac disease patients, headache is one of the most common neurological issues addressed among both adults and children. Headache disorders and CD are highly prevalent in the general population; for this reason, any causal association between these conditions and the role of a gluten-free diet (GFD) has been debated. The aim of this manuscript is to review the current scientific literature regarding the potential association between CD and headaches and the beneficial effects of a GFD. Among the various authors, in our opinion, the current state of the evidence suggests a significant role for the early screening of CD during the initial diagnosis of recurrent headaches, either in adults or children.

4.
Pathogens ; 9(5)2020 May 08.
Artículo en Inglés | MEDLINE | ID: mdl-32397187

RESUMEN

Toxoplasma gondii (TG) is one of the most widespread intracellular parasites in the world, despite the slight declining trend in industrialized countries. Whilst the infection is often asymptomatic in immunocompetent hosts, in immunocompromised patients such as organ transplant recipients it can have important clinical sequels with even fatal consequences. We retrospectively reviewed 568 primary liver transplants (LT) from deceased donors from 2012 to 2017. Data were analyzed adjusting for year, gender, and age. The study objective was to assess the incidence of post-transplant TG infection and adherence to international guidelines for primary chemoprophylaxis. Prior to transplantation, 42.4% of recipients tested seronegative and 56.5% seropositive, while 36.6% of donors were seropositive and 40.4% showed undetermined serology. Anti-TG antibody titer was higher in patients born abroad (71.4%) versus Italy (54.8%). Among recipients at high risk of post-transplant TG infection, 82.7% of them received chemoprophylaxis, while in 17.3% of cases no prophylaxis was administered. At a mean (SD) follow-up of 21.2 (12.4) months no case of TG infection has been observed. Despite the low rate of adherence to recommendations, prophylaxis of high-risk LT recipients provides control of post-transplant TG infection risk. Review of current guidelines is warranted for low-risk populations.

5.
Brain Dev ; 41(5): 456-459, 2019 May.
Artículo en Inglés | MEDLINE | ID: mdl-30642617

RESUMEN

MECP2 duplication syndrome (MECP2 DS) is an X-linked disorder characterized by early-onset hypotonia, poor speech development, recurrent respiratory infections, epilepsy and progressive spasticity. Epilepsy occurs in more than 50% of the affected patients. Generalized tonic-clonic seizures (GTCS) are the most common seizure-type described but atonic seizures, absences and myoclonic seizures have also been reported. Electroencephalographic (EEG) and seizure types occurring in MECP2 DS have been poorly investigated. Here we report on two male siblings carrying a maternally-inherited MECP2 duplication. Patients underwent several EEG recordings and long-lasting video-EEG monitoring. The most represented seizure types were myoclonic and atonic seizures. GTCS were rarely observed. In patients, we found a slowing of the background activity with multifocal paroxysmal activity, prominent on the frontal areas. In conclusion, our observations seem to suggest that MECP2 syndrome seem to have a peculiar epileptic pattern mainly characterized by the occurrence of myoclonic seizures, the recognition of which is important in order to undertake an appropriate treatment.


Asunto(s)
Epilepsia/fisiopatología , Discapacidad Intelectual Ligada al Cromosoma X/fisiopatología , Niño , Electroencefalografía , Epilepsia/etiología , Humanos , Masculino , Discapacidad Intelectual Ligada al Cromosoma X/complicaciones , Linaje
6.
Expert Rev Neurother ; 18(5): 427-434, 2018 05.
Artículo en Inglés | MEDLINE | ID: mdl-29651881

RESUMEN

INTRODUCTION: The brain is particularly susceptible to oxidative stress being the most aerobically active organ in the body due to its high metabolic demands. There is evidence that neuronal hyperexcitability and oxidative injury produced by an excessive production of free radicals may play a role in the initiation and progression of epilepsy. Understanding the role of oxidative stress in epileptogenesis is essential to delineate appropriate therapeutic strategies. Neuroprotectant or antioxidant compounds may exert positive effects when associated with antiepileptic drugs (AEDs). Areas covered: This review aims to outline the current state of knowledge on the relationship between oxidative stress and epilepsy. The role of neuroprotectants in the therapeutic strategy to prevent or treating epilepsy is also discussed. PubMed/Medline database was searched for relevant articles on the relation between oxidative stress and epilepsy and on antioxidant strategies for epilepsy management. Expert commentary: Therapeutic intervention with antioxidants may represent a key strategy to counteract the epilepsy-related neurodegenerative process. However, in spite of the incredible development of new drugs for epilepsy treatment, definitive evidence about the neuroprotective ability of the existing compounds is still lacking. Therefore, there is great need for clinical trials to evaluate new antioxidant compounds specifically on epileptic patients.


Asunto(s)
Epilepsia/metabolismo , Estrés Oxidativo , Anticonvulsivantes/uso terapéutico , Antioxidantes/uso terapéutico , Encéfalo/metabolismo , Epilepsia/tratamiento farmacológico , Radicales Libres , Humanos , Neuroprotección , Fármacos Neuroprotectores/uso terapéutico
7.
Arch Dis Child Fetal Neonatal Ed ; 103(2): F163-F166, 2018 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-28667188

RESUMEN

BACKGROUND: Early-onset neonatal sepsis (EOS) is a serious and potentially life-threatening disease in newborns. C reactive protein (CRP) is the most used laboratory biomarker for the detection of EOS. Little is known about normal reference values of CRP during the perinatal period as several factors are able to influence it. OBJECTIVES: To identify an appropriate range of CRP values in healthy term newborns during the first 48 hours of life. DESIGN: CRP determination was performed in 859 term newborns at 12, 24 and 48 hours of life. Mode of delivery, maternal vaginal culture results, intrapartum antimicrobial prophylaxis (IAP) and other perinatal variables were recorded. RESULTS: CRP mean values were significantly higher at 48 hours (4.10 mg/L) than at both 24 (2.30 mg/L) and 12 hours of life (0.80 mg/L). CRP levels were affected by a number of perinatal proinflammatory variables. In particular, CRP mean values were significantly higher in babies born by vaginal delivery (3.80 mg/L) and emergency caesarean section (3.60 mg/L) than in babies born by elective caesarean section (2.10 mg/L). Completed course of IAP led to lower CRP mean values (2.90 mg/L) than IAP not completed (3.80 mg/L) or not performed (4.70 mg/L). CONCLUSIONS: Postnatal age and mode of delivery significantly influence CRP values. Reliable reference values are crucial in order to obtain an adequate diagnostic accuracy.


Asunto(s)
Proteína C-Reactiva/análisis , Parto Obstétrico/métodos , Profilaxis Antibiótica/métodos , Biomarcadores , Femenino , Humanos , Recién Nacido , Estudios Prospectivos , Valores de Referencia , Vagina/microbiología
8.
Oxid Med Cell Longev ; 2016: 4782426, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27239251

RESUMEN

Oxidative stress is a distinctive sign in several genetic disorders characterized by cancer predisposition, such as Ataxia-Telangiectasia, Fanconi Anemia, Down syndrome, progeroid syndromes, Beckwith-Wiedemann syndrome, and Costello syndrome. Recent literature unveiled new molecular mechanisms linking oxidative stress to the pathogenesis of these conditions, with particular regard to mitochondrial dysfunction. Since mitochondria are one of the major sites of ROS production as well as one of the major targets of their action, this dysfunction is thought to be the cause of the prooxidant status. Deeper insight of the pathogenesis of the syndromes raises the possibility to identify new possible therapeutic targets. In particular, the use of mitochondrial-targeted agents seems to be an appropriate clinical strategy in order to improve the quality of life and the life span of the patients.


Asunto(s)
Síndrome de Beckwith-Wiedemann/metabolismo , Mitocondrias/metabolismo , Enfermedades Mitocondriales/metabolismo , Neoplasias/metabolismo , Estrés Oxidativo , Síndrome de Prader-Willi/metabolismo , Factores de Edad , Animales , Anticarcinógenos/uso terapéutico , Antioxidantes/uso terapéutico , Síndrome de Beckwith-Wiedemann/complicaciones , Síndrome de Beckwith-Wiedemann/tratamiento farmacológico , Síndrome de Beckwith-Wiedemann/genética , Transformación Celular Neoplásica/genética , Transformación Celular Neoplásica/metabolismo , Predisposición Genética a la Enfermedad , Humanos , Mitocondrias/efectos de los fármacos , Enfermedades Mitocondriales/tratamiento farmacológico , Enfermedades Mitocondriales/genética , Neoplasias/genética , Neoplasias/prevención & control , Estrés Oxidativo/efectos de los fármacos , Síndrome de Prader-Willi/complicaciones , Síndrome de Prader-Willi/tratamiento farmacológico , Síndrome de Prader-Willi/genética , Factores de Riesgo
9.
Tumori ; 100(6): 590-9, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25688491

RESUMEN

Oxidative stress plays a key role in carcinogenesis. Oxidative damage to cell components can lead to the initiation, promotion and progression of cancer. Oxidative stress is also a distinctive sign in several genetic disorders characterized by a cancer predisposition such as ataxia-telangiectasia, Fanconi anemia, Down syndrome, Beckwith-Wiedemann syndrome and Costello syndrome. Taking into account the link between oxidative stress and cancer, the capacity of antioxidant agents to prevent or delay neoplastic development has been tested in various studies, both in vitro and in vivo, with interesting and promising results. In recent years, research has been conducted into the molecular mechanisms linking oxidative stress to the pathogenesis of the genetic syndromes we consider in this review, with the resulting identification of possible new therapeutic targets. The aim of this review is to focus on the oxidative mechanisms intervening in carcinogenesis in cancer-prone genetic disorders and to analyze the current status and future prospects of antioxidants.


Asunto(s)
Antioxidantes/uso terapéutico , Enfermedades Genéticas Congénitas/complicaciones , Enfermedades Genéticas Congénitas/metabolismo , Neoplasias/metabolismo , Neoplasias/prevención & control , Estrés Oxidativo , Ataxia Telangiectasia/complicaciones , Ataxia Telangiectasia/metabolismo , Síndrome de Beckwith-Wiedemann/complicaciones , Síndrome de Beckwith-Wiedemann/metabolismo , Carcinogénesis/genética , Carcinogénesis/metabolismo , Síndrome de Costello/complicaciones , Síndrome de Costello/metabolismo , Síndrome de Down/complicaciones , Síndrome de Down/metabolismo , Anemia de Fanconi/complicaciones , Anemia de Fanconi/metabolismo , Humanos , Lactante , Neoplasias/genética , Estrés Oxidativo/efectos de los fármacos , Riesgo
10.
Anticancer Res ; 33(2): 691-5, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23393369

RESUMEN

BACKGROUND: Costello syndrome is a rare genetic condition characterized by coarse facies, short stature, loose folds of skin especially on hands and feet, severe feeding difficulties and failure to thrive. Other features include cardiac anomalies, developmental disability and increased risk of neoplasms. Given the link between oxidative stress (OS) and carcinogenesis, we tested the hypothesis that OS occurs in this syndrome, supposing its role both in cancer development and in other clinical features. PATIENTS AND METHODS: We describe four cases with Costello syndrome in which we verified the presence of OS by measuring a redox biomarker profile including total hydroperoxides, non-protein-bound iron, advanced oxidation protein products, thyols, carbonyl groups and isoprostanes. Thus, we introduced an antioxidant agent, namely potassium ascorbate with ribose (PAR) into the therapy and monitored the redox profile every three months to verify its efficacy. RESULTS: A progressive decrease in OS biomarkers occurred, together with an improvement in the clinical features of the patients. CONCLUSION: OS was proven in all four cases of Costello syndrome. The antioxidant therapy with PAR demonstrated positive effects. These promising results need further research to confirm the relevance of OS and the efficacy of PAR therapy in Costello syndrome.


Asunto(s)
Antioxidantes/uso terapéutico , Ácido Ascórbico/uso terapéutico , Síndrome de Costello/tratamiento farmacológico , Síndrome de Costello/fisiopatología , Estrés Oxidativo , Síndrome de Costello/metabolismo , Femenino , Humanos , Recién Nacido , Masculino , Oxidación-Reducción , Ribosa/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA